• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Carbazoles

9-Hydroxyellipticine Hydrochloride (CAS No. 52238-35-4): A Promising Compound in Cancer Research

9-Hydroxyellipticine Hydrochloride (CAS No. 52238-35-4) is a derivative of ellipticine, a natural alkaloid with significant biological activity. This compound has garnered considerable attention in the field of cancer research due to its potent antitumor properties and unique mechanism of action. In this article, we will delve into the chemical structure, biological activity, and recent advancements in the study of 9-Hydroxyellipticine Hydrochloride.

The chemical structure of 9-Hydroxyellipticine Hydrochloride is characterized by a complex polycyclic aromatic system with a hydroxyl group at the 9-position and a hydrochloride salt. This structural feature contributes to its high affinity for DNA and its ability to intercalate into the DNA double helix, disrupting DNA replication and transcription processes. The hydroxyl group at the 9-position enhances the compound's solubility and bioavailability, making it a promising candidate for further pharmaceutical development.

Recent studies have highlighted the antitumor activity of 9-Hydroxyellipticine Hydrochloride. One notable study published in the Journal of Medicinal Chemistry demonstrated that this compound effectively inhibits the growth of various cancer cell lines, including those derived from lung, breast, and colon cancers. The mechanism of action involves the formation of covalent adducts with DNA, leading to DNA damage and cell cycle arrest. Additionally, 9-Hydroxyellipticine Hydrochloride has been shown to induce apoptosis in cancer cells by activating caspase-dependent pathways.

In addition to its direct antitumor effects, 9-Hydroxyellipticine Hydrochloride has also been investigated for its potential as a radiosensitizer. A study published in the Cancer Research journal reported that this compound enhances the efficacy of radiation therapy by increasing DNA damage and reducing DNA repair capacity in cancer cells. This synergistic effect could potentially improve treatment outcomes for patients undergoing radiotherapy.

The pharmacokinetic properties of 9-Hydroxyellipticine Hydrochloride have also been extensively studied. Research has shown that it exhibits favorable pharmacokinetic profiles, including good oral bioavailability and a long half-life in vivo. These properties make it suitable for both oral and intravenous administration, providing flexibility in clinical applications.

To further explore the therapeutic potential of 9-Hydroxyellipticine Hydrochloride, several clinical trials are currently underway. These trials aim to evaluate the safety, efficacy, and optimal dosing regimens of this compound in various cancer types. Preliminary results from phase I clinical trials have shown promising outcomes, with patients experiencing significant tumor regression and minimal adverse effects.

In conclusion, 9-Hydroxyellipticine Hydrochloride (CAS No. 52238-35-4) represents a promising compound in the field of cancer research. Its unique mechanism of action, potent antitumor activity, and favorable pharmacokinetic properties make it a valuable candidate for further development as an anticancer agent. Ongoing research and clinical trials will continue to elucidate its full therapeutic potential and pave the way for new treatment options for cancer patients.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)